Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?

2 hours ago 1

Jonathan Ponciano, The Motley Fool

Sun, March 22, 2026 astatine 11:28 AM CDT 4 min read

On February 17, 2026, Paradigm Biocapital Advisors LP disclosed a bargain of 750,000 shares of Olema Pharmaceuticals (NASDAQ:OLMA) successful Q4 2025, an estimated $13.35 cardinal commercialized based connected quarter-end pricing.

According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Paradigm Biocapital Advisors accrued its holdings successful Olema Pharmaceuticals by 750,000 shares during the 4th fourth of 2025. The quarter-end worth of the Olema Pharmaceuticals involvement stood astatine $122.09 million.

This was a nett buy, raising the presumption to immoderate 4.5% of Paradigm’s reportable AUM arsenic of December 31, 2025.
Top holdings aft the filing:
- NASDAQ:NUVL: $530.05 cardinal (14.2% of AUM)
- NASDAQ:RVMD: $529.23 cardinal (14.2% of AUM)
- NASDAQ:ACLX: $373.21 cardinal (10.0% of AUM)
- NASDAQ:GMAB: $216.83 cardinal (5.8% of AUM)
- NASDAQ:TARS: $209.79 cardinal (5.6% of AUM)
As of February 17, 2026, Olema Pharmaceuticals shares were priced astatine $14.08, up a staggering 242% implicit the past twelvemonth and importantly outperforming the S&P 500’s astir 15% summation successful the aforesaid period.

Metric

Value

Price (as of Friday)	$14.08
Market capitalization	$1.2 billion
Net income (TTM)	($162.45 million)

Olema Pharmaceuticals develops caller therapies for women's cancers, with its pb candidate, OP-1250, targeting estrogen receptor-positive bosom cancer.
The institution operates a clinical-stage biopharmaceutical concern model, generating worth done the advancement and imaginable commercialization of proprietary cause candidates.
Olema chiefly targets oncologists, healthcare providers, and patients affected by hormone-driven cancers, focusing connected the oncology therapeutics market.

Olema Pharmaceuticals is simply a clinical-stage biotechnology institution specializing successful the improvement of targeted therapies for women's cancers. Its strategy centers connected advancing first-in-class and best-in-class therapeutics, with a absorption connected estrogen receptor antagonists for bosom cancer. The company's competitory borderline lies successful its proprietary cause find level and its pb program, OP-1250.

Biotech investors thrive connected uncertainty, but they request setups that committedness important potential, and Olema is simply a standout successful this regard.

The institution is connected the brink of pivotal Phase 3 information owed aboriginal this year, with an array of pipeline readouts scheduled for 2026. The timing is crucial, particularly for a portfolio already leaning heavy into clinical-stage oncology players similar Nuvalent and Revolution Medicines, wherever occurrence hinges connected objective proceedings outcomes.

Financially, Olema is positioned well. With implicit $500 cardinal successful currency astatine year-end and a caller $200 cardinal superior raise, the institution is acceptable to navigate respective cardinal moments ahead. Ultimately, this blend of currency reserves and upcoming catalysts drives assurance successful positioning. However, the stock's important surge implicit the past twelvemonth raises the stakes. Expectations are high, and immoderate letdown successful proceedings results could rapidly overturn the narrative. Shares person already been tested immoderate this year, falling 44% since the extremity of past quarter.

Read Entire Article